
Cybersecurity World On Edge As CVE Program Prepares To Go Dark
On April 16, a foundational piece of the world's cybersecurity infrastructure may quietly grind to a halt.
MITRE's stewardship of the Common Vulnerabilities and Exposures program—a backbone of coordinated vulnerability disclosure for more than two decades—is facing an uncertain future as its U.S. Department of Homeland Security contract expires. Without confirmed renewal or replacement, the industry risks entering a period of dangerous opacity in vulnerability tracking.
For the cybersecurity community, this isn't a minor bureaucratic lapse. It's a five-alarm fire.
For those outside the security trenches, it's easy to overlook how essential the CVE and CWE – or Common Weakness Enumeration – programs have become. CVEs assign standardized identifiers to software vulnerabilities, making it easier for security researchers, vendors, and IT teams to communicate and prioritize fixes. The CWE program, a related effort, categorizes common coding errors that introduce those vulnerabilities in the first place.
Together, they form the connective tissue for a global ecosystem of security tooling and coordination. From vulnerability scanners to patch management systems and threat intel feeds, thousands of tools and workflows rely on up-to-date CVE data. Vendors use CVEs to issue advisories and coordinate disclosures. Security teams use them to track risks and drive remediation. Even government agencies like CISA and the DoD rely on CVEs as a core part of their threat modeling and defensive planning.
Which is why the looming shutdown is so alarming.
MITRE has confirmed that its DHS contract to manage the CVE and CWE programs is set to lapse on April 16, 2025, and as of now, no renewal has been finalized. This contract, renewed annually, has funded critical work to keep the CVE program running, including updates to the schema, assignment coordination, and vulnerability vetting.
'Failure to renew MITRE's contract for the CVE program, seemingly set to expire on April 16, 2025, risks significant disruption,' said Jason Soroko, Senior Fellow at Sectigo. 'A service break would likely degrade national vulnerability databases and advisories. This lapse could negatively affect tool vendors, incident response operations, and critical infrastructure broadly. MITRE emphasizes its continued commitment but warns of these potential impacts if the contracting pathway is not maintained.'
MITRE has indicated that historical CVE records will remain accessible via GitHub, but without continued funding, the operational side of the program—including assignment of new CVEs—will effectively go dark. That's not a minor inconvenience. It could upend how the global cybersecurity community identifies, communicates, and responds to new threats.
Greg Anderson, CEO and founder of DefectDojo, voiced what many in the community are feeling: 'MITRE's confirmation that it is losing DHS funding to maintain the Common Vulnerabilities and Exposures (CVE) program should concern every cybersecurity professional around the world, especially considering that the funding expires tomorrow—leaving no room for anything to be built in its place.'
Anderson added a sobering thought experiment: 'If, as expected, the database goes offline tomorrow and only GitHub records remain, every security team has just lost an essential resource for early warnings and a cohesive framework for naming and addressing vulnerabilities.'
He explained the risks of a fragmented landscape: 'To illustrate, say a new vulnerability in encryption used across the internet emerges. Without the CVE program, one non-governing body may name the issue 'The worst encryption flaw ever,' but another non-governing body names the issue 'A terrible encryption flaw,' both not using the CVE-20XX-XXXX identification protocol. Without CVEs, how do we even know we're talking about the same issue?'
Anderson warned that 'security professionals are going to have to gather and consolidate information in a piecemeal fashion without CVEs as a central repository, which costs valuable time that could be spent addressing the issues.' He also noted that security professionals have to deal with an overwhelming volume of threats – 40,000+ CVEs that were found last year, plus older vulnerabilities which are still being exploited today.
'Losing CVEs and their database could result in a total collapse of how known vulnerabilities are assessed, communicated, and remediated today,' he concluded.
MITRE has said that discussions with the U.S. government are active and that it remains committed to the CVE mission. But with the expiration date looming, time is running short—and the consequences of even a temporary gap are severe.
'Hopefully this situation gets resolved quickly,' said Casey Ellis, founder at Bugcrowd. 'CVE underpins a huge chunk of vulnerability management, incident response, and critical infrastructure protection efforts. A sudden interruption in services has the very real potential to bubble up into a national security problem in short order.'
Across the cybersecurity ecosystem—from vendors to government agencies—the call is the same: resolve this, and fast.
Whether funding is restored in time or not, this moment should serve as a wake-up call for the industry and policymakers alike. A program as vital as CVE should not be hanging by a thread every April. It needs stable, long-term funding and a robust governance model that ensures continuity, even in the face of bureaucratic delays or shifting political winds.
Cyber threats are evolving faster than ever. Shutting down the CVE program – even briefly – would be like turning off air traffic control mid-flight.
This isn't just about maintaining a database. It's about maintaining trust in the systems that protect us all.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
a day ago
- Forbes
Microsoft Issues Critical Windows Update—Do Not Delete This
You have been warned — do not hit delete. NurPhoto via Getty Images You won't like this. If you're at risk from this Windows security vulnerability, the fix is a nightmare unless you're a fairly expert user. That's not ideal, and it's all down to an update quietly installed on your PC without explanation in April. You may recall the awkward saga of the 'inetpub' folder and 'Microsoft's confusing messaging on deleting or not deleting this mysterious folder on your PC that could leave you and your PC at risk.' Plenty of users deleted the folder that suddenly turned up. 'After installing this update or a later Windows update,' Microsoft later explained, the new folder will appear on your device. 'This folder should not be deleted.' This empty folder, Windows Latest explains, 'is typically associated with Internet Information Services (IIS), which is a native Windows service that allows developers to host websites or apps on Windows 11.' The empty folder appeared without explanation. 'Some of us assumed that it's a bug with the cumulative update and deleted the folder.' Now we have news of an actual fix. 'If you deleted the 'inetpub' folder, created after Windows April 2025 updates,' Windows Latest warns, 'you need to immediately bring it back.' You can turn on the IIS service or 'use a new PowerShell script.' Only after all those deletions did the explanation come. The 'inetpub' folder 'is created as part of a security patch for CVE-2025-21204,' Windows Latest says, 'and it doesn't matter whether IIS is turned on or not. It'll show up, and you're not supposed to delete it, and if you deleted it, please bring it back, according to Microsoft.' You can turn on IIS, 'however, that's something most people don't want to do because IIS also creates additional folders, which are not required unless you're a developer. Instead you can run Microsoft's newly released PowerShell script. First ensure you're logged in as an Administrator, then you can follow Windows Latest's instructions: Mostly users are unlikely to go through this, which will leave them at risk. 'As per Microsoft, without the folder and its correct ACLs (Access Control Lists), you remain exposed to potential privilege escalation or unauthorized access.'
Yahoo
2 days ago
- Yahoo
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: "We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand." "We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations." Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact:Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: "We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand." "We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations." Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact:Neural Therapeutics Inc. Ian Campbell, CEOE: icampbell@ T: +1 (647) 697-NURL (6875) Marc LakmaakerE: mlakmaaker@ +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Sign in to access your portfolio